ALZpath Announces Licensing Agreement with Roche for Use of ALZpath’s Proprietary pTau217 Antibody in Blood Test to Diagnose Alzheimer’s Disease

Agreement Paves the Way for New Era of Accessible, Precise, and Reliable Diagnostic Blood Tests Capable of Identifying Alzheimer’s Disease in its Earliest Stages CARLSBAD, Calif., June 10, 2024 /PRNewswire/ — ALZpath, Inc., a leading developer of innovative diagnostic tools and solutions…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks